These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29574715)

  • 61. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
    Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
    Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
    Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G
    Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.
    Cheung IY; Cheung NV; Modak S; Mauguen A; Feng Y; Basu E; Roberts SS; Ragupathi G; Kushner BH
    J Clin Oncol; 2021 Jan; 39(3):215-226. PubMed ID: 33326254
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
    Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
    Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass.
    Murphy JM; Lim II; Farber BA; Heaton TE; Basu EM; Roberts SS; Modak S; Kushner BH; LaQuaglia MP
    J Pediatr Surg; 2016 Feb; 51(2):285-8. PubMed ID: 26651282
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
    Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.
    Ashraf K; Shaikh F; Gibson P; Baruchel S; Irwin MS
    Pediatr Blood Cancer; 2013 Oct; 60(10):1636-41. PubMed ID: 23650219
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
    van den Bijgaart RJE; Kroesen M; Wassink M; Brok IC; Kers-Rebel ED; Boon L; Heise T; van Scherpenzeel M; Lefeber DJ; Boltje TJ; den Brok MH; Hoogerbrugge PM; Büll C; Adema GJ
    J Biol Chem; 2019 Mar; 294(12):4437-4449. PubMed ID: 30670592
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Iodine 131 labeled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma.
    Cheung NK; Miraldi FD
    Prog Clin Biol Res; 1988; 271():595-604. PubMed ID: 3406022
    [No Abstract]   [Full Text] [Related]  

  • 73. Neuroblastoma in adults and adolescents: an indolent course with poor survival.
    Franks LM; Bollen A; Seeger RC; Stram DO; Matthay KK
    Cancer; 1997 May; 79(10):2028-35. PubMed ID: 9149032
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.
    Modak S; Gerald W; Cheung NK
    Med Pediatr Oncol; 2002 Dec; 39(6):547-51. PubMed ID: 12376975
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma.
    Garaventa A; De Bernardi B; Pianca C; Donfrancesco A; Cordero di Montezemolo L; Di Tullio MT; Bagnulo S; Mancini A; Carli M; Pession A; Arrighini A; Di Cataldo A; Tamaro P; Iasonni V; Taccone A; Rogers D; Boni L;
    J Clin Oncol; 1993 Sep; 11(9):1770-9. PubMed ID: 8355044
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.
    Cheung NK; Munn D; Kushner BH; Usmani N; Yeh SD
    Int J Rad Appl Instrum B; 1989; 16(2):111-20. PubMed ID: 2497088
    [No Abstract]   [Full Text] [Related]  

  • 77. Immunotherapy with GD2 specific monoclonal antibodies.
    Cheung NK; Medof ME; Munn D
    Prog Clin Biol Res; 1988; 271():619-32. PubMed ID: 3043454
    [No Abstract]   [Full Text] [Related]  

  • 78. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.
    Szychot E; Peregud-Pogorzelski J; Wawryków P; Brodkiewicz A
    Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):1001-1004. PubMed ID: 27708204
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.